Chawla, S. P., Blay, J., Ray-Coquard, I. L., Le Cesne, A., Staddon, A. P., Milhem, M. M., … Demetri, G. D. (2011). Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Journal of Clinical Oncology, 29(15_suppl), 10005–10005. https://doi.org/10.1200/jco.2011.29.15_suppl.10005

Chawla, S. P., J. Blay, I. L. Ray-Coquard, A. Le Cesne, A. P. Staddon, M. M. Milhem, N. Penel, et al. “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).” Journal of Clinical Oncology 29, no. 15_suppl (May 20, 2011): 10005–10005. https://doi.org/10.1200/jco.2011.29.15_suppl.10005.

Chawla SP, Blay J, Ray-Coquard IL, Le Cesne A, Staddon AP, Milhem MM, et al. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Journal of Clinical Oncology. 2011 May 20;29(15_suppl):10005–10005.

Chawla, S. P., et al. “Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT).” Journal of Clinical Oncology, vol. 29, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2011, pp. 10005–10005. Crossref, doi:10.1200/jco.2011.29.15_suppl.10005.

Chawla SP, Blay J, Ray-Coquard IL, Le Cesne A, Staddon AP, Milhem MM, Penel N, Riedel RF, Bui Nguyen B, Cranmer LD, Reichardt P, Bompas E, Song Y, Lee R, Eid JE, Loewy J, Haluska FG, Dodion PF, Demetri GD. Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011 May 20;29(15_suppl):10005–10005.